Signals were just the beginning. Fundz is what’s next.
Only Fundz brings more than a dozen live business signals together on each company, ranks every company against your ICP, and each morning delivers the best: who to reach out to, why, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Abcuro, Inc. raises $66 million in Series D financing led by New Leaf Venture Partners to advance its first-in-class medicine for Inclusion Body Myositis.
PRIVATEAug 18, 2026
Amount Raised
$66 Million
Round Type
Series D
NewtonBiotechnologyHealth CareTherapeutics
Investors
Redmile GroupSamsara BiocapitalAbrdn Inc.Bain Capital Life SciencesSamsara Bio CapitalMass General Brigham VenturesRa CapitalNew Leaf Venture Partners
Description
Abcuro, Inc. has successfully closed a $66 million Series D financing. The round was led by New Leaf Venture Partners, with participation from existing investors including abrdn Inc., Bain Capital Life Sciences, and others. The funds will be used to advance its medicine in development for Inclusion Body Myositis
Company Information
Company
Abcuro
Location
Newton, Texas, United States
About
Abcuro, based in Newton MA, is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. The company is conducting two clinical trials in rare diseases: a Phase 2/3 registrational trial evaluating ABC008 in inclusion body myositis (IBM,) and a Phase 1/2 trial evaluating ABC008 in T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com.
Fundz sees it the moment Abcuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NewtonBiotechnologyHealth CareTherapeutics